Presenting at the J.P. Morgan Healthcare Conference can increase Annexon's visibility among investors and industry professionals, potentially leading to a positive impact on its stock price. The focus on late-stage therapies for neuroinflammatory diseases may attract interest due to the advanced stage of development.